Teachers Advisors LLC lifted its stake in shares of Genomic Health (NASDAQ:GHDX) by 12.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,510 shares of the medical research company’s stock after acquiring an additional 4,333 shares during the period. Teachers Advisors LLC’s holdings in Genomic Health were worth $1,351,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Meeder Asset Management Inc. boosted its stake in shares of Genomic Health by 120.7% during the fourth quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock valued at $101,000 after acquiring an additional 1,619 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Genomic Health by 9.6% during the third quarter. New York State Common Retirement Fund now owns 22,900 shares of the medical research company’s stock valued at $735,000 after acquiring an additional 2,000 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Genomic Health by 22.5% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 16,337 shares of the medical research company’s stock valued at $524,000 after acquiring an additional 3,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Genomic Health during the third quarter valued at $138,000. Finally, First National Bank of Omaha boosted its stake in shares of Genomic Health by 17.2% during the fourth quarter. First National Bank of Omaha now owns 30,105 shares of the medical research company’s stock valued at $1,030,000 after acquiring an additional 4,425 shares during the last quarter. 89.99% of the stock is currently owned by institutional investors and hedge funds.
GHDX has been the topic of a number of analyst reports. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “strong sell” rating in a research note on Friday, March 9th. Barclays reaffirmed a “sell” rating and set a $28.00 price objective on shares of Genomic Health in a research note on Monday, January 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $42.00 price objective on shares of Genomic Health in a research note on Tuesday, January 16th. BidaskClub raised Genomic Health from a “hold” rating to a “buy” rating in a research note on Friday, March 30th. Finally, William Blair lowered Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $32.67.
Shares of NASDAQ:GHDX opened at $32.53 on Thursday. Genomic Health has a 12-month low of $26.54 and a 12-month high of $37.50. The stock has a market capitalization of $1,176.66, a price-to-earnings ratio of 3,253.00 and a beta of 0.63.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Thursday, March 8th. The medical research company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Genomic Health had a negative return on equity of 0.83% and a negative net margin of 1.13%. The business had revenue of $87.50 million during the quarter, compared to analyst estimates of $88.96 million. During the same period in the previous year, the business posted $0.04 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. equities analysts predict that Genomic Health will post 0.42 earnings per share for the current year.
In other news, insider Kimberly J. Popovits sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $33.19, for a total value of $497,850.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $32.89, for a total value of $164,450.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,942 shares of company stock worth $1,317,895. 46.20% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/19/teachers-advisors-llc-has-1-35-million-position-in-genomic-health-ghdx.html.
Genomic Health Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.